A pharmaceutical analysis method, apparatus, system, medium, and device

Abstract

This application provides a drug analysis method, apparatus, system, medium, and device. A drug analysis method includes: acquiring drug information; acquiring an analysis script package and generating script package attribute information, wherein the script package attribute information includes at least one of version number, creation time, creation user, and script remarks; associating the analysis script package with analysis templates and drug profiles, wherein each analysis template is associated with at least one drug profile, and each drug profile is associated with one analysis script package; running scripts in the analysis script package to process data of drug analysis instances matching the analysis templates and drug profiles to obtain analysis data; and forming analysis conclusions based on the analysis data. Accordingly, this application also provides apparatus, systems, media, and devices related to the drug analysis method.

Description

Technical Field

[0001] This application belongs to the field of pharmaceutical data statistical analysis technology, and particularly relates to a pharmaceutical analysis method, apparatus, system, medium and equipment. Background Technology

[0002] With the development of big data technology, various fields are increasingly adopting big data and intelligent technologies to process and analyze data. The medical industry, as a traditional sector, has been deeply influenced by big data and artificial intelligence, and the full development and utilization of the value of medical data is receiving increasing attention from the industry. In the era of big data, the digitization of medical data has broken down the previously relatively closed system of the medical industry, allowing people to easily use electronic medical data to analyze various medical-related issues such as diseases and drugs.

[0003] However, when companies need to analyze massive amounts of medical data, data analysts typically need to use statistical tools on their local computers to collect, clean, model, and standardize the data to generate analytical data and draw conclusions. Data analysts often need to use similar statistical methods to analyze different datasets, leading to repetitive work. They frequently need to use the same statistical methods to clean and analyze different datasets, which is time-consuming and prevents them from freeing up to perform more in-depth work. Furthermore, inconsistencies in the versions of shared scripts used by different data analysts often increase the complexity of maintaining these scripts.

[0004] Application content

[0005] To overcome the aforementioned deficiencies in the prior art, this application provides a pharmaceutical analysis method, the method comprising:

[0006] Obtain the analysis script package and generate script package attribute information, wherein the script package attribute information includes at least one of the following: version number, creation time, creation user, and script remarks;

[0007] The analysis script package is associated with the analysis template and the drug profile, and each analysis template is associated with at least one drug profile, and each drug profile is associated with one analysis script package;

[0008] The analysis script package is run to process the data of drug analysis instances that match the analysis template and drug profile to obtain analysis data;

[0009] The analytical conclusions of the drug analysis example are formed based on the analyzed data.

[0010] According to one aspect of this application, the analysis script in the method includes a script file and a configuration file, and the step of obtaining the analysis script package and generating script package attribute information includes: verifying the script package to determine whether the script package meets the set requirements.

[0011] According to another aspect of this application, the method of running the analysis script package to process data of a drug analysis instance that matches the analysis template and drug profile to obtain analysis data includes: decomposing the script file into multiple task units of different programming statistical languages ​​according to the data of the drug analysis instance and the configuration file; calling the language engine corresponding to the programming statistical language of the task unit to execute the task unit; and combining the execution results of each task unit to obtain the analysis data.

[0012] According to another aspect of this application, before running the analysis script package to process the data of drug analysis instances matching the analysis template and drug profile to obtain analysis data, the method further includes: determining an analysis template based on information about the drug analysis instance, wherein the drug analysis information includes at least one of drug information, execution method, statistical method, and statistical type; and using the drug profile associated with the analysis template as the matching profile for the drug analysis instance.

[0013] According to another aspect of this application, the method of using the drug profile associated with the analysis template as the matching profile of the drug analysis instance includes: when the number of drug profiles associated with the analysis template is 1, using the drug profile associated with the analysis template as the matching profile of the drug analysis instance; when the number of drug profiles associated with the analysis template is greater than 1, using one of the drug profiles associated with the analysis template as the matching profile of the drug analysis instance.

[0014] According to another aspect of this application, the method of using one of the drug profiles associated with the analysis template as the matching profile of the drug analysis instance includes: obtaining drug information in the drug analysis instance, and determining the number of tag matches and the matching rate of each drug profile based on the drug information and the tags of the drug profiles; sorting the drug profiles according to the number of tag matches and the matching rate of each drug profile, and selecting the drug profile with the largest number of matches and / or matching rate as the matching profile of the drug analysis instance; when the number of matches and / or matching rates of the drug profiles are the same, selecting the drug profile with the most recent creation and / or update time as the matching profile of the drug analysis instance.

[0015] According to another aspect of this application, after using the drug profile associated with the analysis template as the matching profile of the drug analysis instance, the method further includes: determining the required drug data based on the matching profile of the drug analysis instance; and calling a retrieval script to search the target drug database to obtain the drug data based on the required drug data.

[0016] According to another aspect of this application, the drug data in the method includes at least one of: drug registration data, drug clinical research information, drug indications, drug target population, drug dosage, drug route of administration, drug combination therapy, drug sequential therapy information, and drug competitor information.

[0017] According to another aspect of this application, the target drug database in the method includes at least one of the following: a registration database, a review database, a clinical database, a literature database, a disease-specific database, and a real-world database.

[0018] According to another aspect of this application, the method further includes: visualizing the analyzed data to obtain a visualization chart; and forming the analytical conclusion based on the visualization chart.

[0019] According to another aspect of this application, the method also includes: creating different analysis templates and drug profiles for different medical research projects.

[0020] In addition, this application provides a pharmaceutical analysis apparatus, which includes:

[0021] The script acquisition module is used to acquire the analysis script package and generate script package attribute information, which includes at least one of the following: version number, creation time, creation user, and script remarks.

[0022] The script association module is used to associate the analysis script package with the analysis template and the drug profile, wherein each analysis template is associated with at least one drug profile and each drug profile is associated with one analysis script package;

[0023] The script execution module is used to run the analysis script package to process the data of the drug analysis instance that matches the analysis template and drug profile to obtain analysis data;

[0024] The conclusion formation module is used to form analytical conclusions for the drug analysis example based on the analytical data.

[0025] In addition, this application provides a pharmaceutical analysis system, which includes:

[0026] The drug analysis client obtains the analysis script package and generates script package attribute information. The script package attribute information includes at least one of the following: version number, creation time, creation user, and script remarks. The client also associates the analysis script package with analysis templates and drug profiles. Each analysis template is associated with at least one drug profile, and each drug profile is associated with one analysis script package.

[0027] The script execution backend is used to run the analysis script package to process the data of the drug analysis instance that matches the analysis template and drug profile, so as to obtain analysis data and form analysis conclusions of the drug analysis instance based on the analysis data.

[0028] In addition, this application provides one or more computer-readable media storing computer-executable instructions that, when used by one or more computer devices, cause the one or more computer devices to perform the pharmaceutical analysis method as described above.

[0029] This application also provides a computer device, the computer device including a memory and a processor, wherein: the memory stores a computer program, and the processor executes the computer program to implement the drug analysis method as described above.

[0030] The drug analysis method provided in this application generates script package attribute information simultaneously when creating the analysis script package. This attribute information clearly identifies the script package's version number, creation time, creator, and script remarks, thus clarifying the purpose and applicable statistical scope of each script package and reducing the likelihood of incomplete analysis reports due to incorrect script selection. Furthermore, the method pre-creates multiple drug profiles and analysis templates, associating each profile with its corresponding script package. When executing a drug analysis instance, simply matching the analysis template and drug profile to the instance automatically runs the associated script package, processing the data to obtain analytical conclusions. This automates drug analysis, freeing analysts from repetitive tasks. The pre-defined drug profiles and templates, each with different focuses, allow analysts to complete drug analysis projects without requiring specialized industry experience or a deep understanding of industry data. Moreover, the method allows for the continuous creation of various drug profiles based on drug characteristics to meet the needs of research institutions or enterprises, improve statistical models, and enhance team collaboration efficiency. Attached Figure Description

[0031] Other features, objects, and advantages of this application will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings:

[0032] Figure 1 This is a flowchart illustrating a specific implementation of the pharmaceutical analysis method according to this application;

[0033] Figure 2 yes Figure 1 The diagram shows a preferred embodiment of obtaining drug data in step S300.

[0034] Figure 3 This is a flowchart illustrating another optional specific implementation of the pharmaceutical analysis method according to this application;

[0035] Figure 4 This is a flowchart illustrating a preferred specific implementation of the drug profiling matching method;

[0036] Figure 5 This is a flowchart illustrating another optional specific implementation of the pharmaceutical analysis method according to this application;

[0037] Figure 6 yes Figure 1 The flowchart shown is a preferred embodiment of obtaining drug data in step S400;

[0038] Figure 7 A bar chart analyzing the number of patients using XX injection for new indications in F City over the past three years;

[0039] Figure 8 A bar chart analyzing the number of patients using XX injection for new indications in F city over the past 3 years.

[0040] Figure 9 This is a schematic diagram of an optional specific embodiment of the pharmaceutical analysis apparatus according to this application;

[0041] Figure 10 This is a schematic diagram of an optional specific embodiment of the drug analysis system according to this application;

[0042] Figure 11 This is a schematic diagram of a typical computing device used to implement the pharmaceutical analysis method of this application;

[0043] The same or similar reference numerals in the accompanying drawings represent the same or similar parts. Detailed Implementation

[0044] To better understand and explain this application, a further detailed description will be provided below with reference to the accompanying drawings. This application is not limited to these specific embodiments. Rather, any modifications or equivalent substitutions made to this application should be covered within the scope of the claims.

[0045] It should be noted that numerous specific details are provided in the following detailed embodiments. Those skilled in the art should understand that this application can be implemented without these specific details. In the various detailed embodiments given below, principles, structures, and components well known in the art are not described in detail in order to highlight the main points of this application.

[0046] The terminology used in this article is as follows:

[0047] Drug profiling: A type of data profiling, where the data comes from statistics from different data sources, hence it can also be called statistical profiling; different drug profiles correspond to different analytical directions, statistical types, and statistical methods.

[0048] Analysis templates are created in advance in the system according to the methodology. The analysis templates include corresponding business item nodes configured according to different business needs. Different analysis templates have different execution methods and analysis content.

[0049] Script package: Includes script files and configuration files; different scripts are used for different analysis projects.

[0050] This application discloses a drug analysis method; please refer to [reference needed]. Figure 1 , Figure 1 This is a flowchart illustrating a specific embodiment of the pharmaceutical analysis method according to this application, the method comprising:

[0051] Step S100: Obtain the analysis script package and generate script package attribute information, wherein the script package attribute information includes at least one of version number, creation time, creation user, and script remarks;

[0052] Step S200: Associate the analysis script package with the analysis template and the drug profile, wherein each analysis template is associated with at least one drug profile and each drug profile is associated with one analysis script package;

[0053] Step S300: Run the analysis script package to process the data of the drug analysis instance that matches the analysis template and drug profile to obtain analysis data;

[0054] Step S400: Based on the analysis data, form the analysis conclusion of the drug analysis example.

[0055] In step S100, the acquired analysis script package can be an analysis script package uploaded by the analyst from the client. After acquiring the analysis script package uploaded by the analyst from the client, script package attribute information is generated synchronously. The script package attribute information includes at least one of the following: version number, creation time, creating user, and script remarks. In this way, when analysts select script packages later, they can clarify the purpose and applicable statistical scope of each script package based on the attribute information of the analysis script package, thereby selecting the appropriate analysis script package and reducing the situation where the analysis report cannot be generated due to the selection of the wrong script.

[0056] For example, in one embodiment of this application, the analysis script package includes a statistical model script and instructions for using the script configuration file; that is, the analysis script includes a script file and a configuration value file. The data analysis script contains multiple encapsulated statistical equation modules that can automatically calculate based on input variables. The script configuration file records and explains the statistical types, statistical methods, and corresponding statistical parameters supported by the scripts in the analysis script package, and details the rules for filling in the variables. The script package uploaded to the system supports script version management, recording the script package creation time and the user who created it for future traceability.

[0057] For example, in one embodiment of this application, step S100 further includes: verifying the script package to determine whether the script package meets the set requirements.

[0058] Specifically, the system first verifies whether the uploaded script file and configuration file name meet the system requirements, and then verifies whether the file extension of the uploaded script is a statistical tool type supported by the system.

[0059] In step S200, the analysis script package is associated with analysis templates and drug profiles. Each analysis template is associated with at least one drug profile, and each drug profile is associated with one analysis script package. The analysis templates and drug profiles can be pre-established or newly established. After obtaining the analysis script package, it can be associated with its applicable analysis templates and drug profiles.

[0060] For example, the drug profile and analysis template can be established before step S1100 or between steps S100 and S200, and this application does not limit this.

[0061] For example, different project analysis templates can be created based on medical approaches developed from experience in the medical and clinical industries to address various project analysis problems. For each medical approach, a corresponding project analysis template is created in the system, and a research plan is formulated. Each project analysis template covers different research paths, each research path encompasses different execution methods, and each execution method represents a statistical business module that needs to be analyzed. Each execution method includes statistical tasks for multiple sub-projects, and the titles of the sub-projects within the execution method specify the content of the analysis.

[0062] For example, for a new commercial application of a drug, a commercial exploration project analysis template for clinical evidence development of drug xx can be created. The execution method of this project analysis template includes two sub-projects: the distribution of the number of patients with the new drug indication and the distribution of the number of prescriptions for the new drug indication. These two sub-projects indicate that the project analysis template needs to statistically analyze the distribution of the number of patients with the new drug indication and the distribution of the number of prescriptions for the new drug indication.

[0063] For example, corresponding drug profiles can be created for project analysis templates based on different business needs. For instance, for the business of developing clinical evidence for innovative drugs, drug profiles tagged with original drugs, pediatric drugs, and medical insurance coverage can be created. These drug profiles are applicable to clinical evidence development analysis project examples for drugs with original drug, pediatric drug, and medical insurance coverage information.

[0064] It should be understood that drug profiles can be created to meet a wide variety of requirements based on the research direction and type of the drug. For each project analysis template, multiple drug profiles can be created, and when performing a specific project analysis instance, the closest drug profile can be matched or a new, suitable drug profile can be created.

[0065] For example, the analysis template for the clinical evidence development and commercial exploration project of drug xx can include drug profiles labeled as original drug, pediatric drug, and covered by medical insurance, or it can include drug profiles labeled as original drug, adult drug, and covered by medical insurance.

[0066] After creating a drug profile, the script parameter configuration page allows you to select the appropriate script package, statistical type, and statistical method based on different execution methods. Statistical types include, but are not limited to, descriptive statistical analysis, inferential statistical analysis, and visual statistical analysis. Different statistical types encompass various statistical methods; for example, inferential statistical types include algebraic tests, linear regression, and hypothesis testing. When facing new drug needs, corresponding statistical models can be configured according to the research plan developed by medical professionals. For instance, if a medical research plan requires studying the annual distribution of patient visit types for a specific drug indication, the statistical analyst can select the bar chart method within the bar chart visualization statistical analysis type and set the corresponding parameters to clearly and intuitively visualize the distribution of patient visit types through a bar chart.

[0067] An example of a drug profile is shown in the table below:

[0068]

[0069] The following table shows an example of how to configure drug profiles:

[0070]

[0071]

[0072] It should be understood that in this application, each drug profile is associated with an analysis template and an analysis script package. The associated analysis template represents the medical approach, research plan, research path, and execution method used for analyzing the drug profile. The analysis script package is used to analyze the drug data corresponding to the drug profile to obtain the analytical conclusions required by the corresponding analysis template.

[0073] Each drug profile has a corresponding label, which indicates which type of drug the profile corresponds to in the analysis.

[0074] Through the above steps, the drug analysis method of this application embodiment, by pre-setting multiple analysis templates and drug profiles, and configuring a corresponding analysis script package for each profile, can automatically complete the drug analysis by matching the drug profile and running the corresponding script package, which greatly improves the analysis efficiency and frees analysts from repetitive work.

[0075] Step S300: Run the analysis script package to process the data of the drug analysis instance that matches the analysis template and drug profile to obtain analysis data.

[0076] For example, the data in the drug analysis instance includes drug data.

[0077] In one embodiment of this application, the drug data includes at least one of the following: drug registration data, drug clinical research information, drug indications, drug target population, drug dosage, drug route of administration, drug combination therapy, drug sequential therapy information, and drug competitor information. It should be understood that the drug data may include one or more of the above data.

[0078] For example, in one embodiment of this application, drug data is represented as a data table. The column names in the table are variable names that can be statistically analyzed. These column names refer to column names found in, for example, drug registration data, drug clinical trial information tables, etc. These column names are all treated as different variables and analyzed.

[0079] After acquiring the drug data, the analysis script package is run to process the data of the drug analysis instance that matches the analysis template and drug profile, thereby obtaining the analysis data.

[0080] In step S400, an analysis conclusion is formed based on the analysis data.

[0081] For example, in one embodiment of this application, statistical conclusions are obtained by statistically analyzing the data, and these conclusions are used as the analysis conclusions.

[0082] Please refer to Figure 2 , Figure 2 yes Figure 1 The diagram illustrates a preferred embodiment of obtaining drug data in step S300. Preferably, step S300, which involves running the analysis script package to process data from drug analysis instances matching the analysis template and drug profile to obtain analysis data, includes:

[0083] Step S310: Based on the data of the drug analysis instance and the configuration file, the script file is decomposed into multiple task units, and the task units employ at least one programming statistical language;

[0084] Step S320: Call the language engine corresponding to the programming statistical language of the task unit to execute the task unit;

[0085] Step S330: Combine the execution results of each task unit to obtain the analysis data.

[0086] In step S310, the data in the drug analysis instance includes drug information and drug data. Drug information includes at least one of the following: drug classification, drug origin, drug type, clinical need, drug status, medical insurance status, and patent status. Drug data includes at least one of the following: drug registration data, drug clinical research information, drug indications, target population, drug dosage, route of administration, combination therapy, sequential therapy, and competitor information.

[0087] In this embodiment, the drug information, drug data, and script configuration files all have corresponding input parameter specifications. After acquiring this data, the parameters are validated according to these specifications. If a parameter does not meet the requirements, a data anomaly warning is issued. If the parameters meet the requirements, the script file is decomposed into multiple task units using different statistical programming languages ​​based on the data from the drug analysis example and the configuration file. For example, each task unit uses at least one statistical programming language. For instance, the first task unit might use R, the second task unit might use SAS, and the third task unit might use Python.

[0088] In step S320, the language engine corresponding to the programming statistical language of the task unit is invoked to execute the task unit.

[0089] Specifically, the decomposed task units are iterated over, and statistical language judgments are performed on each task unit within the loop. The language engine corresponding to the programming statistical language of the task unit is then invoked to execute the task unit. For example, for a task unit using the R language, the R language engine is invoked to execute the task unit.

[0090] In step S330, the execution results of each task unit are summarized to obtain the analysis data of the drug analysis instance.

[0091] Please refer to Figure 3 , Figure 3 This is a flowchart illustrating another optional specific embodiment of the pharmaceutical analysis method according to this application. Figure 1 The difference in the specific implementation shown is that, after step S200 and before S300, Figure 3 The optional embodiments shown also include:

[0092] Step S400: Create a drug analysis instance based on the analysis template, wherein the drug analysis instance includes at least drug information;

[0093] Step S500: Use the drug profile associated with the analysis template as the matching profile of the drug analysis instance.

[0094] In step S400, when creating a drug analysis instance, a pre-established analysis template can be used. For example, for the Xiyanping clinical evidence development commercial exploration analysis instance, a xx drug clinical evidence development commercial exploration analysis template can be used, which defines the required drug information.

[0095] For example, a specific example of drug information is shown in the table below:

[0096] type value Drug Classification Class 1 innovative chemical drugs Drug origin Original drug Types of medicines Children's medicine Clinical demand Non-clinical continuation Drug status It has been listed overseas. Medical insurance status Medical Insurance Patent status During the patent term

[0097] Step S500: Use the drug profile associated with the analysis template as the matching profile of the drug analysis instance.

[0098] For example, when the number of drug images associated with the analysis template is one, the drug image associated with the analysis template is used as the matching image for the drug analysis instance; when the number of drug images associated with the analysis template is greater than one, one of the drug images associated with the analysis template is used as the matching image for the drug analysis instance. In other words, when the analysis template includes only one drug image, that drug image is used as the matching image for the drug analysis instance. When the analysis template includes multiple images, one drug image is selected as the matching image for the drug analysis instance according to a preset rule.

[0099] Please refer to Figure 4 , Figure 4 This is a flowchart illustrating a preferred specific implementation of the drug profiling and matching method. For example... Figure 4 As shown, the drug profile matching process includes:

[0100] Step S610: Obtain drug information in the drug analysis instance, and determine the number of tag matches and the matching rate of each drug profile based on the drug information and the tags of the drug profile;

[0101] Step S620: Sort the drug images according to the number of matching tags and the matching rate of each drug image, and select the drug image with the largest number of matching tags and / or the largest matching rate as the matching image of the drug analysis instance;

[0102] Step S630: When the number of matches and / or the match rate of the drug profiles are the same, select the drug profile with the latest creation and / or update time as the matching profile of the drug analysis instance.

[0103] In step S610, based on the drug information of the current drug analysis project instance, the tag matching number and matching rate of each drug profile in the analysis template are determined. The tag matching number of a drug profile refers to the number of shared information between the drug profile's tags and the drug information. For example, if the drug information is "medical insurance drug, traditional Chinese medicine, marketed drug," and the tags of drug profile A are "medical insurance drug, biological drug," then the tag matching number of drug profile A is 1, because only the medical insurance drug is shared between the two.

[0104] The tag matching rate of a drug profile refers to the ratio of the number of matching information items in the drug profile tags to the total number of information items. For example, if the drug information is "medical insurance drug, traditional Chinese medicine, marketed drug", and the tags of drug profile A are "medical insurance drug, biological drug", then the tag matching rate of drug profile A is 1 / 2 or 0.5.

[0105] In step S620, the drug images are sorted according to the number of matching tags and the matching rate of each drug image, and the drug image with the largest number of matching tags and / or the largest matching rate is selected as the matching image of the drug.

[0106] For example, in one embodiment of this application, the drug profile with the highest number of tag matches can be selected as the matching profile, that is, the drug profile with the most shared information with the drug information among the tags is selected as the matching profile. For example, if the tag match count of drug profile A is 1, the tag match count of drug profile B is 2, and the tag match count of drug profile C is 3, then drug profile C is selected as the matching profile of the drug.

[0107] For example, in one embodiment of this application, the drug profile with the highest tag matching rate can be selected as the matching profile, that is, the drug profile with the largest proportion of common information in the tags is selected as the matching profile. For example, if the tag matching rate of drug profile A is 1, the tag matching rate of drug profile B is 0.5, and the tag matching rate of drug profile C is 0.4, then drug profile A is selected as the matching profile of the drug.

[0108] For example, in one embodiment of this application, the drug image with the largest number of matches is selected as the matching image of the drug; when the number of matches is the same, the drug image with the largest matching rate is selected as the matching image of the drug.

[0109] For example, in a drug project instance, if the drug information is "medicine covered by medical insurance, traditional Chinese medicine, marketed drug", drug profile A is tagged with "medicine covered by medical insurance, biological drug", with a tag match count of 1 and a tag match rate of 1 / 2 = 0.5; drug profile B is tagged with "traditional Chinese medicine, marketed drug", with a tag match count of 2 and a tag match rate of 2 / 2 = 1; drug profile C is tagged with "medicine covered by medical insurance, traditional Chinese medicine, marketed drug", with a tag match count of 3 and a tag match rate of 3 / 3 = 1; drug profile D is tagged with "medicine covered by medical insurance, traditional Chinese medicine, marketed drug, adult drug", with a tag match count of 3 and a tag match rate of 3 / 4 = 0.75.

[0110] First, we compare the number of tag matches. The highest number of tag matches is 3, so we exclude profiles A and B. Since the tag match rate of profile C is greater than that of D, we choose profile C as the matching profile for the drug.

[0111] In step S630, when the number of matches and / or the match rate of the drug profiles are the same, the drug profile with the latest creation and / or update time is selected as the matching profile of the drug analysis instance.

[0112] That is, if multiple drug profiles with the highest and / or the same matching number and matching rate appear in step S620, the drug profile with the latest creation and / or update time is selected as the matching profile of the drug analysis instance.

[0113] For example, if the matching rate of drug profile A and drug profile B is both 1, and the creation time of drug profile A is July 10, 2022, while the creation time of drug profile B is June 10, 2022, then drug profile A is selected as the matching profile for the drug analysis instance.

[0114] In the above manner, the drug analysis method of this application can match the most similar drug profile from the analysis template, thereby using the most similar drug profile to analyze the drug data to obtain the required analysis conclusions.

[0115] Please refer to Figure 5 , Figure 5 This is a flowchart illustrating another optional specific embodiment of the pharmaceutical analysis method according to this application. Figure 3 The difference in the specific implementation shown is that, after step S600 and before S300, Figure 5 The optional embodiments shown also include:

[0116] Step S210: Determine the required drug data based on the matching profile of the drug.

[0117] Step S220: Search the target drug database to obtain the required drug data.

[0118] For example, in one embodiment of this application, the drug data includes at least one of the following: drug registration data, drug clinical research information, drug indications, drug target population, drug dosage, drug route of administration, drug combination therapy, drug sequential therapy information, and drug competitor information. It should be understood that the drug data may include one or more of the above data.

[0119] Step S700: The required drug data can be determined based on the matching profile of the drug analysis instance;

[0120] Step S800: Based on the required drug data, call the retrieval script to search the target drug database to obtain the corresponding drug data.

[0121] In step S700, the required drug data can be determined based on the matching profile of the drug analysis instance. Specifically, the required drug data for the current drug analysis instance is determined based on the matching profile, including which of the following data are needed: drug registration data, drug clinical research information, drug indications, target population, drug dosage, route of administration, combination therapy, sequential therapy information, and competitor information. For example, if the analysis template associated with drug profile A is "commercial exploration of clinical evidence development for drug xx," and the execution method is "distribution of the number of patients with new drug indications," then the required drug data is drug indication data.

[0122] Once the required drug data is obtained in S700, the corresponding drug data is retrieved from the target drug database.

[0123] For example, in one embodiment of this application, the target drug database includes at least one of the following: a registration database, a review database, a clinical database, a literature database, a disease-specific database, and a real-world database.

[0124] For example, in one embodiment of this application, when the required drug data is obtained in S700, the corresponding drug data is retrieved from the corresponding target drug data. For instance, when drug registration data is required, the drug registration data is retrieved from the registration database.

[0125] Through the above methods, the drug analysis method of this application embodiment can match drug profiles based on drug information and retrieve drug data based on drug profiles, thereby improving the convenience of data acquisition, reducing the workload of analysts, and improving analysis efficiency.

[0126] It should be understood that drug data is not limited to obtaining it through database retrieval as mentioned above; it can also be entered by analysts through the system's data transmission or input terminals. Alternatively, it can be obtained through both analyst input and automated retrieval.

[0127] It should be understood that the drug analysis method in this application can also visualize the analytical data to facilitate a more intuitive understanding of the analytical conclusions. Please refer to... Figure 6 , Figure 6 yes Figure 1 The diagram illustrates a preferred embodiment of obtaining drug data in step S400. Preferably, the step of forming an analytical conclusion based on the analytical data in step S400 includes:

[0128] Step S410: Visualize the analyzed data to obtain a visualization chart.

[0129] Step S420: Form the analysis conclusion based on the visualization chart.

[0130] For example, in one embodiment of this application, in step S410, the analytical data obtained in step S300 is processed by a visualization script to obtain a visualization chart. The specific process is as follows: First, the type of chart to be drawn can be determined according to the type of analytical data. The chart type is, for example, a bar chart, a line chart, a pie chart, a Sankey diagram, a heat map, a box-and-whisker diagram, etc.; then, according to different chart types, the corresponding analytical data is read and the chart is generated.

[0131] In step S420, the analysis conclusion is formed based on the visualization chart. For example, an analysis script can automatically form the analysis conclusion based on the visualization chart.

[0132] See an example of a visualization of charts and analytical conclusions. Figure 7 and Figure 8 As shown, Figure 7 A bar chart analyzing the number of patients using XX injection for new indications in F City over the past three years; Figure 8 A bar chart analyzing the number of patients using XX injection for new indications in F City over the past three years.

[0133] according to Figure 7 According to the analysis of real-world data from F City over the past three years, the largest number of patients with hand-foot-mouth disease were infected, reaching 110,000; followed by patients with bacterial infections, reaching 70,000.

[0134] according to Figure 8 According to real-world data analysis from F City over the past three years, the number of medical orders for hand-foot-mouth disease was the highest, reaching 300,000 times; followed by the number of medical orders for dysentery, reaching 100,000 times.

[0135] according to Figure 7 and Figure 8 The following conclusions can be drawn from the analysis:

[0136] Based on the analysis of patient populations and medication orders, the following three directions for developing new indications have a higher probability of success:

[0137] 1. Analysis of the efficacy and safety of XX injection in the treatment of hand-foot-mouth disease, with a recommendation level of 4 stars.

[0138] 2. Analysis of the efficacy and safety of XX injection in treating bacterial infections, with a recommendation level of 3 stars.

[0139] 3. Analysis of the efficacy and safety of XX injection in the treatment of dysentery, recommendation level 3.

[0140] The above charts and analytical conclusions can be obtained automatically through scripts processing drug data, without the need for manual operation.

[0141] This application also discloses a drug analysis device; please refer to [reference needed]. Figure 9 , Figure 9 This is a schematic flowchart of a specific embodiment of the pharmaceutical analysis apparatus according to this application, the apparatus comprising:

[0142] The script acquisition module 100 is used to acquire the analysis script package and generate script package attribute information, wherein the script package attribute information includes at least one of version number, creation time, creation user and script remarks information;

[0143] The script association module 200 is used to associate the analysis script package with the analysis template and the drug profile, wherein each analysis template is associated with at least one drug profile and each drug profile is associated with one analysis script package;

[0144] The script execution module 300 is used to run the analysis script package to process the data of the drug analysis instance that matches the analysis template and drug profile to obtain analysis data;

[0145] The conclusion forming module 400 is used to form the analytical conclusion of the drug analysis example based on the analytical data.

[0146] In one embodiment of this application, the analysis script includes a script file and a configuration file. The script acquisition module 100 is further configured to verify the script to determine whether the script package meets the set requirements.

[0147] In one embodiment of this application, the script execution module 300 includes:

[0148] A decomposition unit is used to decompose the script file into multiple task units based on the data of the drug analysis instance and the configuration file, wherein the task units employ at least one programming statistical language.

[0149] An execution unit is used to call a language engine corresponding to the programming statistical language of the task unit to execute the task unit;

[0150] The summarization unit is used to synthesize the execution results of each task unit to obtain the analysis data.

[0151] In one embodiment of this application, the apparatus further includes a first creation module for creating a drug analysis instance based on an analysis template, wherein the drug analysis instance includes at least drug information;

[0152] The drug profile associated with the analysis template is used as the matching profile for the drug analysis instance.

[0153] In one embodiment of this application, the device further includes a profile matching module, configured to use the drug profile associated with the analysis template as the matching profile of the drug analysis instance when the number of drug profiles associated with the analysis template is 1; and to use one of the drug profiles associated with the analysis template as the matching profile of the drug analysis instance when the number of drug profiles associated with the analysis template is greater than 1.

[0154] In one embodiment of this application, the profile matching module is further configured to: obtain drug information in the drug analysis instance, and determine the number of tag matches and the matching rate of each drug profile based on the drug information and the tags of the drug profiles; sort the drug profiles according to the number of tag matches and the matching rate of each drug profile, and select the drug profile with the largest number of matches and / or matching rate as the matching profile of the drug analysis instance; when the number of matches and / or matching rates of the drug profiles are the same, select the drug profile with the latest creation and / or update time as the matching profile of the drug analysis instance.

[0155] In one embodiment of this application, the device further includes a data acquisition module, used to determine the required drug data based on the matching profile of the drug analysis instance; and to call a retrieval script to search the target drug database to obtain the drug data based on the required drug data.

[0156] In one embodiment of this application, the conclusion forming module 400 includes a visualization submodule for visualizing the analysis data to obtain a visualization chart; and a conclusion forming submodule for forming the analysis conclusion based on the visualization chart.

[0157] In one embodiment of this application, the device further includes a second creation module for creating different analysis templates and drug profiles according to different medical research projects.

[0158] The functions of each module in each device of the embodiments of this application can be found in the corresponding descriptions in the above methods, and will not be repeated here.

[0159] This application also discloses a drug analysis system; please refer to [reference needed]. Figure 10 , Figure 10 This is a schematic diagram of an optional specific embodiment of the drug analysis system according to this application. For example... Figure 10 As shown, the system includes:

[0160] The drug analysis client 1010 is used to obtain analysis script packages and generate script package attribute information. The script package attribute information includes at least one of version number, creation time, creation user and script remarks information, and associates the analysis script package with analysis templates and drug profiles. Each analysis template is associated with at least one drug profile, and each drug profile is associated with one analysis script package.

[0161] The script execution backend 1020 is used to run the analysis script package to process the data of the drug analysis instance that matches the analysis template and drug profile, so as to obtain analysis data and form the analysis conclusion of the drug analysis instance based on the analysis data.

[0162] For example, in one embodiment of this application, the drug analysis client 1010 can be implemented as a local client or a web client.

[0163] For example, the drug analysis client 1010 may include an input module for inputting information about the drug analysis instance, uploading analysis script packages, etc.

[0164] For example, the drug analysis client 1010 may include a creation module for creating drug profiles, analysis templates, drug analysis instances, etc.

[0165] For example, the drug analysis client 1010 may include a profile matching module for matching profiles to drug analysis instances.

[0166] For example, the drug analysis client 1010 may include a data acquisition module for retrieving drug databases and acquiring drug data.

[0167] For example, the script execution backend 1020 can be implemented as a server.

[0168] For example, the script execution backend 1020 includes a script execution engine for running the analysis script package to process data of drug analysis instances that match the analysis template and drug profile to obtain analysis data.

[0169] For example, the script execution backend 1020 includes a conclusion forming module for forming an analysis conclusion of the drug analysis instance based on the analysis data.

[0170] For example, the script execution backend 1020 can execute various statistical languages, including but not limited to R, SAS, Python, etc.

[0171] The drug analysis system provided in this application allows for script package uploading, drug profiling, analysis module creation, and drug analysis instance creation on the drug analysis client 1010, while data processing and conclusion output are completed on the script execution backend 1020. This system can provide drug analysis services to different analysts, improving processing efficiency.

[0172] It should be noted that although the operations of the method of this application are described in a specific order in the accompanying drawings, this does not require or imply that these operations must be performed in that specific order, or that all the operations shown must be performed to achieve the desired result. On the contrary, the steps depicted in the flowchart can be executed in a different order. Additionally or alternatively, certain steps may be omitted, multiple steps may be combined into one step, and / or one step may be broken down into multiple steps.

[0173] Please refer to Figure 11 , Figure 11This is a schematic diagram of a typical computer device used to execute a specific embodiment of the drug analysis method of the present invention. More specifically, the drug analysis apparatus described above can be included as part of this computer device. The computer device includes at least the following components: CPU (Central Processing Unit) 501, RAM (Random Access Memory) 502, ROM (Read-Only Memory) 503, system bus 500, hard disk control unit 504, hard disk 505, human-computer interaction external device control unit 506, human-computer interaction external device 507, serial interface control unit 508, serial interface external device 509, parallel interface control unit 510, parallel interface external device 511, display device control unit 512, and display device 513. The CPU 501, RAM 502, ROM 503, hard disk control unit 504, human-computer interaction external device control unit 506, serial interface control unit 508, parallel interface control unit 510, and display device control unit 512 are connected to the system bus 500 and communicate with each other through the system bus 500. In addition, the hard disk control unit 504 is connected to the hard disk 505; the human-computer interaction external device control unit 506 is connected to the human-computer interaction external device 507, typically a mouse, trackball, touch screen, or keyboard; the serial interface control unit 508 is connected to the serial interface external device 509; the parallel interface control unit 510 is connected to the parallel interface external device 511; and the display device control unit 512 is connected to the display device 513.

[0174] Figure 11 The structural block diagrams described herein merely illustrate the structure of a computer device in which the various embodiments of the present invention can be practiced, and are not intended to limit the scope of practice of the invention. In some cases, some devices in the computer device may be added or removed as needed. For example, Figure 11 The device shown can remove the human-computer interaction external device 507 and the display device 513; its specific implementation is simply a server that can be accessed by external devices. Of course... Figure 11 The computer devices shown can independently implement the operating environment of the present invention, or they can be interconnected through a network to provide the operating environment applicable to the various specific embodiments of the present invention. For example, the various modules and / or steps of the present invention can be distributed and implemented in various interconnected computer devices.

[0175] Accordingly, this application also discloses one or more computer-readable media storing computer-executable instructions, which, when used by one or more computer devices, cause the one or more computer devices to perform various specific embodiments of the pharmaceutical analysis method described above, for example... Figure 1The pharmaceutical analysis method is shown. The computer-readable medium can be any available medium accessible by a computer device, including volatile and non-volatile media, removable and non-removable media implemented in any way and with any technique to store information such as computer-readable instructions, data structures, program modules, or other data. Computer-readable media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or other memory technologies, CD-ROM, digital versatile disc (DVD) or other optical storage, cassette tape, magnetic tape, disk storage or other magnetic storage devices, or any other medium that can be used to store the required information and is accessible by a computing device. Any combination of the above should also be included within the scope of computer-readable media.

[0176] Accordingly, this application also discloses a computer device, which includes a memory and a processor, wherein: the memory stores a computer program, and the processor executes the computer program to implement various specific embodiments of the drug analysis method described above, for example... Figure 1 The drug analysis method shown is illustrated.

[0177] The software logic portion of the pharmaceutical analysis method provided in this application can be implemented using a programmable logic device or as a computer program product that enables a computer to execute the demonstrated method. The computer program product includes a computer-readable storage medium containing computer program logic or code portions for implementing the various steps of the aforementioned software logic portion. The computer-readable storage medium can be an internal medium installed in a computer or a removable medium (e.g., a hot-swappable storage device) removable from the computer body. The internal medium includes, but is not limited to, rewritable non-volatile memory, such as RAM, ROM, and hard disks. The removable medium includes, but is not limited to: optical storage media (e.g., CD-ROMs and DVDs), magneto-optical storage media (e.g., MOs), magnetic storage media (e.g., magnetic tapes or portable hard disks), media with built-in rewritable non-volatile memory (e.g., memory cards), and media with built-in ROM (e.g., ROM cartridges).

[0178] Those skilled in the art will understand that any computer system with suitable programming means is capable of executing the steps of the methods of this application contained in a computer program product. Although most of the specific embodiments described in this specification focus on software programs, alternative embodiments that implement the methods provided in this application in hardware are also within the scope of protection claimed in this application.

[0179] It will be apparent to those skilled in the art that this application is not limited to the details of the exemplary embodiments described above, and that this application can be implemented in other specific forms without departing from the spirit or essential characteristics of this application. Therefore, the embodiments should be considered exemplary and not restrictive, and the scope of this application is defined by the appended claims rather than the foregoing description. All variations within the meaning and scope of equivalents of the claims are included within this application. No reference numerals in the claims should be construed as limiting the scope of the claims. Furthermore, it is clear that the word "comprising" does not exclude other components, units, or steps, and the singular does not exclude the plural. Multiple components, units, or devices recited in the claims may also be implemented by a single component, unit, or device through software or hardware.

[0180] The drug analysis method provided in this application generates script package attribute information simultaneously when creating the analysis script package. This attribute information clearly identifies the script package's version number, creation time, creator, and script remarks, thus clarifying the purpose and applicable statistical scope of each script package and reducing the likelihood of incomplete analysis reports due to incorrect script selection. Furthermore, the method pre-creates multiple drug profiles and analysis templates, associating each profile with its corresponding script package. When executing a drug analysis instance, simply matching the analysis template and drug profile to the instance automatically runs the associated script package, processing the data to obtain analytical conclusions. This automates drug analysis, freeing analysts from repetitive tasks. The pre-defined drug profiles and templates, each with different focuses, allow analysts to complete drug analysis projects without requiring specialized industry experience or a deep understanding of industry data. Moreover, the method allows for the continuous creation of various drug profiles based on drug characteristics to meet the needs of research institutions or enterprises, improve statistical models, and enhance team collaboration efficiency.

[0181] The above-disclosed embodiments or specific implementations are only a part of the embodiments or specific implementations of this application and should not be construed as limiting the scope of the rights of this application. Equivalent changes made in accordance with the claims of this application shall still fall within the scope of this application.

Claims

1. A method for analyzing a drug, the method comprising: obtaining an analysis script package and generating script package attribute information, the script package attribute information including at least one of a version number, a creation time, a creation user, and script note information; associating the analysis script package with an analysis template and a drug profile, each of the analysis template being associated with at least one of the drug profile, and each of the drug profile being associated with one of the analysis script package; running the analysis script package to process data of a drug analysis instance matching the analysis template and the drug profile to obtain analysis data; forming an analysis conclusion of the drug analysis instance according to the analysis data; before running the analysis script package to process data of a drug analysis instance matching the analysis template and the drug profile to obtain analysis data, the method further comprising: creating a drug analysis instance according to an analysis template, the drug analysis instance including at least drug information; when a number of drug profiles associated with the analysis template is one, using the drug profile associated with the analysis template as a matching profile of the drug analysis instance; when the number of drug profiles associated with the analysis template is more than one, obtaining drug information in the drug analysis instance and determining a label matching number and a matching rate of each of the drug profiles according to the drug information and labels of the drug profiles; sorting the drug profiles according to the label matching number and the matching rate of each of the drug profiles, and selecting the drug profile with the largest matching number and / or matching rate as the matching profile of the drug analysis instance; when the matching number and / or the matching rate of the drug profiles are the same, selecting the drug profile with the latest creation and / or update time as the matching profile of the drug analysis instance.

2. The method of analyzing a pharmaceutical product according to claim 1, wherein, the analysis script includes a script file and a configuration file, and the obtaining an analysis script package and generating script package attribute information comprises: verifying the script to determine whether the script package meets a set requirement.

3. The method of analyzing a pharmaceutical product according to claim 2, wherein, the running the analysis script package to process data of a drug analysis instance matching the analysis template and the drug profile to obtain analysis data comprises: decomposing the script file into a plurality of task units according to data of the drug analysis instance and the configuration file, the task units using at least one programming statistical language; calling a language engine corresponding to the programming statistical language of the task unit to execute the task unit; integrating execution results of each of the task units to obtain the analysis data.

4. The method of analyzing a pharmaceutical product according to claim 1, wherein: after using the drug profile associated with the analysis template as the matching profile of the drug analysis instance, the method further comprising: determining required drug data according to the matching profile of the drug analysis instance; calling a search script to search a target drug database to obtain the drug data according to the required drug data.

5. The method of analyzing a pharmaceutical product according to claim 4, wherein: the drug data includes at least one of drug registration data, drug clinical research information, a drug indication, a drug target population, a drug dosage application, a drug administration route, a drug combination, drug sequential regimen information, and drug competitor information.

6. The method of analyzing a pharmaceutical product according to claim 4, wherein: The target drug database comprises at least one of a registration database, a review database, a clinical database, a literature database, a special disease database and a real world database.

7. The method of analyzing a pharmaceutical product according to claim 1, wherein: The analysis conclusion of the drug analysis instance is formed according to the analysis data. The analysis data is visualized to obtain a visual chart; The analysis conclusion is formed according to the visual chart.

8. The method of analyzing a pharmaceutical product according to claim 1, wherein: Before the analysis script package is associated with the analysis template and the drug portrait, the method further comprises: Different analysis templates and drug portraits are created according to different medical research projects.

9. A drug analysis device, comprising: A script acquisition module is configured to acquire an analysis script package and generate script package attribute information, wherein the script package attribute information comprises at least one of a version number, a creation time, a creation user and script note information; A script association module is configured to associate the analysis script package with an analysis template and a drug portrait, wherein each analysis template is associated with at least one drug portrait, and each drug portrait is associated with one analysis script package; A script execution module is configured to run the analysis script package to process data of a drug analysis instance matched with the analysis template and the drug portrait, so as to obtain analysis data; A conclusion forming module is configured to form an analysis conclusion of the drug analysis instance according to the analysis data; Before running the analysis script package to process data of a drug analysis instance matched with the analysis template and the drug portrait, so as to obtain analysis data, the method further comprises: A drug analysis instance is created according to an analysis template, wherein the drug analysis instance comprises at least drug information; When the number of drug portraits associated with the analysis template is one, the drug portrait associated with the analysis template is used as a matched portrait of the drug analysis instance; When the number of drug portraits associated with the analysis template is more than one, drug information in the drug analysis instance is acquired, and a label matching number and a matching rate of each drug portrait are determined according to the drug information and labels of the drug portraits; The drug portraits are sorted according to the label matching number and the matching rate of each drug portrait, and the drug portrait with the largest matching number and / or matching rate is selected as the matched portrait of the drug analysis instance; When the matching number and / or the matching rate of the drug portraits are the same, the drug portrait with the latest creation and / or update time is selected as the matched portrait of the drug analysis instance.

10. A drug analysis system, comprising: A drug analysis client is configured to acquire an analysis script package, generate script package attribute information, associate the analysis script package with an analysis template and a drug portrait, wherein the script package attribute information comprises at least one of a version number, a creation time, a creation user and script note information, each analysis template is associated with at least one drug portrait, and each drug portrait is associated with one analysis script package; A script execution backend is configured to run the analysis script package to process data of a drug analysis instance matched with the analysis template and the drug portrait, so as to obtain analysis data, and form an analysis conclusion of the drug analysis instance according to the analysis data; Before running the analysis script package to process data of a drug analysis instance matched with the analysis template and the drug image, further comprising: creating a drug analysis instance according to the analysis template, wherein the drug analysis instance at least comprises drug information; when the number of drug images associated with the analysis template is 1, using the drug image associated with the analysis template as the matched image of the drug analysis instance; when the number of drug images associated with the analysis template is greater than 1, obtaining drug information in the drug analysis instance, and determining the label matching number and matching rate of each drug image according to the drug information and the label of the drug image; sorting the drug images according to the label matching number and matching rate of each drug image, and selecting the drug image with the largest matching number and / or matching rate as the matched image of the drug analysis instance; when the matching number and / or matching rate of the drug images are the same, selecting the drug image with the latest creation and / or update time as the matched image of the drug analysis instance.

11. One or more computer-readable media storing computer-executable instructions that, when used by one or more computer devices, cause the one or more computer devices to perform the method of analyzing a drug according to any one of claims 1 to 8.

12. A computer device, comprising a memory and a processor, wherein: the memory stores a computer program, and the processor implements the method of analyzing a drug according to any one of claims 1 to 8 when executing the computer program.

Images